Recurrent diffuse alveolar haemorrhage in a patient with systemic lupus erythematosus: long-term benefit of rituximab

Lupus. 2012 Sep;21(10):1124-7. doi: 10.1177/0961203312444171. Epub 2012 Mar 29.

Abstract

Diffuse alveolar haemorrhage (DAH) is an uncommon complication of systemic lupus erythematosus (SLE), and recurrences of DAH with remission periods are unusual. We describe a young woman with cachexia as the initial manifestation of SLE who presented posterior reversible encephalopathy syndrome (PRES), intestinal vasculitis and four episodes of DAH even though she was receiving combined immune suppressive therapy. After treatment with rituximab (RTX) the patient has not presented further episodes of DAH.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Cachexia / etiology
  • Female
  • Hemorrhage / complications*
  • Hemorrhage / therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases / complications*
  • Lung Diseases / therapy*
  • Lupus Erythematosus, Systemic / complications*
  • Lupus Erythematosus, Systemic / diagnosis
  • Lupus Erythematosus, Systemic / therapy*
  • Posterior Leukoencephalopathy Syndrome / complications
  • Posterior Leukoencephalopathy Syndrome / diagnosis
  • Posterior Leukoencephalopathy Syndrome / therapy
  • Pulmonary Alveoli
  • Recurrence
  • Rituximab
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Immunosuppressive Agents
  • Rituximab